This patent application, combined with the previously filed Application PCT AU2023/051121 for an improved process for recovery of refractory ores, completes the suite of intellectual property ...

Thank you for standing by, and welcome to Agenus first quarter 2024 results conference call. [Operator instructions] Thank ...

Darzalex (daratumumab) is a monoclonal antibody drug currently approved for both refractory and new multiple myeloma. It’s available in intravenous and subcutaneous formulations.

De Grey Mining has prepped itself for debt financing at its mega Hemi gold mine after announcing a mammoth $600m equity raising.

Additionally, by the end of this year we plan to present initial dose escalation data for CB-011 in relapsed or refractory multiple myeloma.” Clinical highlights CB-010, a clinical-stage allogeneic ...

ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory ...

G&A Expenses: General and administrative expenses were $26.6 million for the first quarter of 2024 compared to $18.0 million for the first quarter of 2023. The increase was primarily due to additional ...

In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initi | ...

Patients with TP53/PPM1D mutations in their stem cell product had an increased risk of myeloid neoplasms in patients with ...

Operator: Good afternoon, ladies and gentlemen, and welcome to the Q1 2024 Kura Oncology Financial Results Conference Call.

The company also disclosed preliminary financial results for the first quarter of 2024. Research and development expenses increased to $6.0 million for the quarter as compared to $5.4 million for the ...